Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
545
-
Total 13F shares, excl. options
-
92.3M
-
Shares change
-
-158K
-
Total reported value, excl. options
-
$12.2B
-
Value change
-
+$5.24M
-
Put/Call ratio
-
0.8
-
Number of buys
-
268
-
Number of sells
-
-242
-
Price
-
$131.76
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q4 2023
617 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q4 2023.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 545 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 92.3M shares
of 99.6M outstanding shares and own 92.69% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13.6M shares), VANGUARD GROUP INC (9.71M shares), STATE STREET CORP (4.06M shares), Bellevue Group AG (2.43M shares), MORGAN STANLEY (2.33M shares), RENAISSANCE TECHNOLOGIES LLC (1.99M shares), JPMORGAN CHASE & CO (1.74M shares), GEODE CAPITAL MANAGEMENT, LLC (1.62M shares), JANUS HENDERSON GROUP PLC (1.55M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.48M shares).
This table shows the top 545 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.